Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | CASR | P41180 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449025 | 0.87 | ACHE (0.48) | ACHEMEN1KMT2ASLC6A9SLC6A4 | |
| SCHEMBL16448458 | 0.79 | OPRM1 (0.50) | MEN1KMT2ASLC6A9SLC6A4SLC6A2 | |
| SCHEMBL16448459 | 0.76 | OPRM1 (0.51) | SLC6A4SLC6A2 | |
| SCHEMBL4152522 | 0.74 | SLC6A9 (0.74) | ACHEMEN1KMT2ASLC6A9NOTUM | |
| SCHEMBL4152516 | 0.74 | SLC6A9 (0.74) | ACHEMEN1KMT2ASLC6A9NOTUM | |
| SCHEMBL4156838 | 0.74 | SLC6A9 (0.74) | ACHEMEN1KMT2ASLC6A9NOTUM | |
| SCHEMBL4156833 | 0.74 | SLC6A9 (0.74) | ACHEMEN1KMT2ASLC6A9NOTUM | |
| SCHEMBL4152529 | 0.74 | SLC6A9 (0.74) | ACHEMEN1KMT2ASLC6A9NOTUM | |
| SCHEMBL17071844 | 0.73 | GPR139 (0.47) | FFAR1SLC6A4GPR139SLC6A2 | |
| SCHEMBL18682089 | 0.72 | GPR139 (0.46) | FFAR1SLC6A4GPR139SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8952169-B2 | N-substituted benzamides and methods of use thereof | XENON PHARMACEUTICALS INC. (CA) | 2015-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002017-A1 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SNRPD2 | ACHE 532/4885MEN1 2017/4885KMT2A 1449/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | ACHE 698/4885MEN1 1307/4885KMT2A 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.